Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052897 · ClinicalTrials.gov registry record · Phase 1
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
A Phase 1 study of Anal Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00052897: Completed Phase 1 study of Anal Cancer, sponsored by National Cancer Institute (NCI).
NCT00052897 is a Phase 1 study of Anal Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00052897, a Phase 1 study of Anal Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia. Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. SGN-00101 may be effective in preventing anal cancer.
Conditions Studied
Interventions
- BIOLOGICAL HspE7
Study Locations (1)
California
- UCSF Comprehensive Cancer Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2002-12 |
| Phase | Phase 1 |
What the finished NCT00052897 record still lists
NCT00052897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 1 intervention - of which HspE7 is the first listed.
NCT00052897 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00052897 about?
NCT00052897 is a clinical study titled "SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia". Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia. Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. SGN-00101 may be effective in preventing anal cancer.
What is the current status of trial NCT00052897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2002-12.
What conditions does trial NCT00052897 study?
This clinical trial studies the following conditions: Anal Cancer.
What interventions are being tested in trial NCT00052897?
The interventions under investigation include: HspE7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00052897?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00052897 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00052897's enrollment target sits among peer trials
18 18th of 19 higher than 2 of 19 other Anal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
ACTIVE NOT RECRUITING · Phase 1
-
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies
RECRUITING
-
Self-sampling to Optimize Anal Lesion Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia